Buonfrate D, Requena-Mendez A, Angheben A, Munoz J, Gobbi F, Van Den Ende J, et al. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis 2013;13:78. https://www.ncbi.nlm.nih.gov/pubmed/23394259
Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C, et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014;44(12b):1350–63. https://www.ncbi.nlm.nih.gov/pubmed/25482745
Fardet L, Genereau T, Poirot JL, Guidet B, Kettaneh A, Cabane J. Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review. J Infect 2007;54(1):18–27. https://www.ncbi.nlm.nih.gov/pubmed/16533536
Lehman JS, Kalaaji AN. Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions. J Am Acad Dermatol 2010;63(5):815–23. https://www.ncbi.nlm.nih.gov/pubmed/20643496
Mejia R, Nutman TB. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 2012;25(4):458–63. https://www.ncbi.nlm.nih.gov/pubmed/22691685
Schar F, Trostdorf U, Giardina F, Khieu V, Muth S, Marti H, et al. Strongyloides stercoralis: Global Distribution and Risk Factors. PLoS Negl Trop Dis 2013;7(7):e2288. https://www.ncbi.nlm.nih.gov/pubmed/23875033
